These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 15934864

  • 1. Reactivation of hepatitis B virus with rituximab.
    Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, Masauzi N.
    Expert Opin Drug Saf; 2005 May; 4(3):599-608. PubMed ID: 15934864
    [Abstract] [Full Text] [Related]

  • 2. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
    Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, Asaka M, Imamura M, Masauzi N.
    Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
    [Abstract] [Full Text] [Related]

  • 3. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
    Huang H, Cai Q, Lin T, Lin X, Liu Y, Gao Y, Peng R.
    Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
    [Abstract] [Full Text] [Related]

  • 4. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma.
    He YF, Li YH, Wang FH, Jiang WQ, Xu RH, Sun XF, Xia ZJ, Huang HQ, Lin TY, Zhang L, Bao SP, He YJ, Guan ZZ.
    Ann Hematol; 2008 Jun; 87(6):481-5. PubMed ID: 18299831
    [Abstract] [Full Text] [Related]

  • 5. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
    Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK.
    J Clin Oncol; 2009 Feb 01; 27(4):605-11. PubMed ID: 19075267
    [Abstract] [Full Text] [Related]

  • 6. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
    Endo T, Sakai T, Fujimoto K, Yamamoto S, Takashima H, Haseyama Y, Nishio M, Koizumi K, Koike T, Sawada K.
    Bone Marrow Transplant; 2001 Feb 01; 27(4):433-6. PubMed ID: 11313673
    [Abstract] [Full Text] [Related]

  • 7. Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis.
    Coiffier B.
    Cancer Invest; 2006 Feb 01; 24(5):548-52. PubMed ID: 16939967
    [Abstract] [Full Text] [Related]

  • 8. Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab.
    Hernández JA, Diloy R, Salat D, del Río N, Martínez X, Castellví JM.
    Haematologica; 2003 Jun 01; 88(6):ECR22. PubMed ID: 12801855
    [No Abstract] [Full Text] [Related]

  • 9. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.
    Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ, Johnson PJ.
    Breast Cancer Res Treat; 2004 Dec 01; 88(3):209-15. PubMed ID: 15609123
    [Abstract] [Full Text] [Related]

  • 10. Rituximab-associated infections.
    Gea-Banacloche JC.
    Semin Hematol; 2010 Apr 01; 47(2):187-98. PubMed ID: 20350666
    [Abstract] [Full Text] [Related]

  • 11. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial.
    Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, Liao YM, Li CC, Wu HB, Tien HF, Chao TY, Liu TW, Cheng AL, Chen PJ.
    Hepatology; 2008 Mar 01; 47(3):844-53. PubMed ID: 18302293
    [Abstract] [Full Text] [Related]

  • 12. The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis.
    Lim ST, Fei G, Quek R, Lim LC, Lee LH, Yap SP, Loong S, Tao M.
    Eur J Haematol; 2007 Aug 01; 79(2):132-7. PubMed ID: 17635237
    [Abstract] [Full Text] [Related]

  • 13. Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab.
    Miyagawa M, Minami M, Fujii K, Sendo R, Mori K, Shimizu D, Nakajima T, Yasui K, Itoh Y, Taniwaki M, Okanoue T, Yoshikawa T.
    J Med Virol; 2008 Dec 01; 80(12):2069-78. PubMed ID: 19040281
    [Abstract] [Full Text] [Related]

  • 14. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.
    Li YH, He YF, Jiang WQ, Wang FH, Lin XB, Zhang L, Xia ZJ, Sun XF, Huang HQ, Lin TY, He YJ, Guan ZZ.
    Cancer; 2006 Mar 15; 106(6):1320-5. PubMed ID: 16470607
    [Abstract] [Full Text] [Related]

  • 15. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy--a prospective case series.
    Vassiliadis T, Garipidou V, Tziomalos K, Perifanis V, Giouleme O, Vakalopoulou S.
    Am J Hematol; 2005 Nov 15; 80(3):197-203. PubMed ID: 16247746
    [Abstract] [Full Text] [Related]

  • 16. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.
    Perceau G, Diris N, Estines O, Derancourt C, Lévy S, Bernard P.
    Br J Dermatol; 2006 Nov 15; 155(5):1053-6. PubMed ID: 17034541
    [Abstract] [Full Text] [Related]

  • 17. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
    Wu JM, Huang YH, Lee PC, Lin HC, Lee SD.
    J Clin Gastroenterol; 2009 Nov 15; 43(5):496-8. PubMed ID: 19247200
    [Abstract] [Full Text] [Related]

  • 18. Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-Hodgkin's lymphoma.
    Wasmuth JC, Fischer HP, Sauerbruch T, Dumoulin FL.
    Eur J Med Res; 2008 Oct 27; 13(10):483-6. PubMed ID: 19008178
    [Abstract] [Full Text] [Related]

  • 19. Prevention of hepatitis B virus reactivation under rituximab therapy.
    Tsutsumi Y, Yamamoto Y, Tanaka J, Asaka M, Imamura M, Masauzi N.
    Immunotherapy; 2009 Nov 27; 1(6):1053-61. PubMed ID: 20635919
    [Abstract] [Full Text] [Related]

  • 20. Fatal reactivation of occult hepatitis B virus infection after rituximab and chemotherapy in lymphoma: necessity of antiviral prophylaxis.
    Zhang B, Wang J, Xu W, Wang L, Ni W.
    Onkologie; 2010 Nov 27; 33(10):537-9. PubMed ID: 20926902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.